Don't Sell Celgene - Cramer's Lightning Round (7/30/08)

Stocks discussed in the lightning round session of Jim Cramer’s Mad Money TV program, Wednesday, July 30.

 

Bullish Calls:

Verizon (VZ) -- "This is the single best wireless business. I like the dividend and I like AT&T (T) also. The analysts love Comcast (CMCSA), but I like Verizon and I am not worried about FiOS."

Celgene (CELG) -- “I never lost faith in Celgene. I want to own biotech in any slow down and we have it. Don’t sell any Celgene.”

Alcoa (AA) -- “Natural gas is one of their biggest costs. I see raw costs going down and I see a cheap stock in the Dow that I want to own, and that company is Alcoa."

Bearish Calls:

ION Geophysical (IO) -- “Don’t mess with ION. They are in seismic exploration and I would rather see you in CoreLabs (CLB).”

Double Hull Tankers (DHT) -- "I only like two tankers, Nordic American Tanker Shipping (NAT) and Frontline (FRO). Don't mess with any of the others."

Ford (F) -- “Too hard. The problem with Ford is the common stock is not the best way to play it. I can't recommend the common stock. It is too speculative.”

Red Robin Gourmet Burgers (RRGB) -- “I am not a fan. Let’s play Panera Bread (PNRA), their CEO was on the show and told a good story over there.”

Eastman Kodak (EK) -- "No, Kodak is a serial disappointer. I am not buying - their competition is too hard."

Seeking Alpha publishes a summary of Jim Cramer's stock picks every day including: Mad Money Recap, Lightning Round and Stop Trading!

Get Cramer's Picks by e-mail -- it's free and takes only a few seconds to sign up.

Seeking Alpha is not affiliated with Jim Cramer, CNBC or TheStreet.com

 

Comments

[Mark Moran:]

Cramer did lose faith in Celgene, but its giant army of loyalists who know it best did not. The near-term is absolutely brilliant, with international and label expansion of Revlimid sales, and Vidaza stealing all of Dacogen's thunder. And that's all that most investors care to hear about. But many who know the company best believe that several products in the pipeline have real potential to be far bigger even than Revlimid - starting with the next one likely to hit the market, Apremilast, which is an oral Enbrel.

2008 Aug 01 04:07 PM